Winther, Jeanette F; Kenborg, Line; Byrne, Julianne; Hjorth, Lars; Kaatsch, Peter; Kremer, Leontien C M; Kuehni, Claudia E; Auquier, Pascal; Michel, Gérard; de Vathaire, Florent; Haupt, Riccardo; Skinner, Roderick; Madanat-Harjuoja, Laura M; Tryggvadottir, Laufey; Wesenberg, Finn; Reulen, Raoul C; Grabow, Desiree; Ronckers, Cecile M; van Dulmen-den Broeder, Eline; van den Heuvel-Eibrink, Marry M; ... (2015). Childhood cancer survivor cohorts in Europe. Acta oncologica, 54(5), pp. 655-668. Acta Oncologica 10.3109/0284186X.2015.1008648
Text
Winther ActaOncol 2015.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (742kB) |
|
Text
Winther ActaOncol 2015_supplmat.pdf - Supplemental Material Restricted to registered users only Available under License Publisher holds Copyright. Download (46kB) |
With the advent of multimodality therapy, the overall five-year survival rate from childhood cancer has improved considerably now exceeding 80% in developed European countries. This growing cohort of survivors, with many years of life ahead of them, has raised the necessity for knowledge concerning the risks of adverse long-term sequelae of the life-saving treatments in order to provide optimal screening and care and to identify and provide adequate interventions. Childhood cancer survivor cohorts in Europe. Considerable advantages exist to study late effects in individuals treated for childhood cancer in a European context, including the complementary advantages of large population-based cancer registries and the unrivalled opportunities to study lifetime risks, together with rich and detailed hospital-based cohorts which fill many of the gaps left by the large-scale population-based studies, such as sparse treatment information. Several large national cohorts have been established within Europe to study late effects in individuals treated for childhood cancer including the Nordic Adult Life after Childhood Cancer in Scandinavia study (ALiCCS), the British Childhood Cancer Survivor Study (BCCSS), the Dutch Childhood Oncology Group (DCOG) LATER study, and the Swiss Childhood Cancer Survivor Study (SCCSS). Furthermore, there are other large cohorts, which may eventually become national in scope including the French Childhood Cancer Survivor Study (FCCSS), the French Childhood Cancer Survivor Study for Leukaemia (LEA), and the Italian Study on off-therapy Childhood Cancer Survivors (OTR). In recent years significant steps have been taken to extend these national studies into a larger pan-European context through the establishment of two large consortia - PanCareSurFup and PanCareLIFE. The purpose of this paper is to present an overview of the current large, national and pan-European studies of late effects after childhood cancer. This overview will highlight the strong cooperation across Europe, in particular the EU-funded collaborative research projects PanCareSurFup and PanCareLIFE. Overall goal. The overall goal of these large cohort studies is to provide every European childhood cancer survivor with better care and better long-term health so that they reach their full potential, and to the degree possible, enjoy the same quality of life and opportunities as their peers.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM) |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Kühni, Claudia, Schindler, Matthias |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0284-186X |
Publisher: |
Acta Oncologica |
Language: |
English |
Submitter: |
Doris Kopp Heim |
Date Deposited: |
17 Apr 2015 10:44 |
Last Modified: |
05 Dec 2022 14:45 |
Publisher DOI: |
10.3109/0284186X.2015.1008648 |
PubMed ID: |
25813473 |
BORIS DOI: |
10.7892/boris.67663 |
URI: |
https://boris.unibe.ch/id/eprint/67663 |